Likang Life Sciences
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing engineered cell therapies for cancer and autoimmune diseases.
OncologyImmunology
Technology Platform
A proprietary platform for engineering T cells and other immune cells with enhanced anti-tumor activity and safety profiles.
Opportunities
Significant market potential in China for advanced cell therapies targeting both hematological and solid tumors.
Risk Factors
High clinical development costs and intense competition pose risks to successful commercialization.
Competitive Landscape
Operates in the crowded but high-growth Chinese CAR-T market, competing with firms like JW Therapeutics and Gracell Biotechnologies.